<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43678">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02075125</url>
  </required_header>
  <id_info>
    <org_study_id>PANTASTIC</org_study_id>
    <nct_id>NCT02075125</nct_id>
  </id_info>
  <brief_title>Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction</brief_title>
  <official_title>Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare efficacy and safety of prasugrel and ticagrelor in patients with ST-segment
      elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prasugrel and ticagrelor are recommended in patients with ST-segment elevation myocardial
      infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Both
      prasugrel and ticagrelor show more rapid and potent antiplatelet effect compared with
      clopidogrel. However, previous report comparing the efficacy and safety of prasugrel and
      ticagrelor in patients with STEMI of East Asian ethnicity is lacking. Therefore, the aim of
      this study is to compare the antiplatelet efficacy and safety using laboratory platelet
      function tests and clinical outcomes in patients with STEMI treated with either prasugrel or
      ticagrelor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>High on-Treatment Platelet Reactivity</measure>
    <time_frame>48 hours after PCI</time_frame>
    <safety_issue>No</safety_issue>
    <description>Platelet reactivity will be measured using VerifyNow (Accumetrics, San Diego, CA, USA) and vasodilator-stimulated phosphoprotein (VASP) phosphorylation. VASP/P2Y12 assay (BioCytex, Marseille, France) and FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) will be used. Measurement time gap +/- 12 hours will be allowed. High on-Treatment Platelet Reactivity (HTPR) is defined as the result of platelet reaction unit (PRU) ≥242 and vasodilator-stimulated phosphoprotein (VASP) index ≥50%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular Events</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any MACE including (death, myocardial infarction, stroke, and revascularization procedure with PCI or CABG) until day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding event</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any event related to bleeding including access site bleeding and peri-procedural bleeding based on BARC criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reaction</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any adverse reaction related to study drug until 30 days after PCI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-procedure platelet reactivity</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Platelet reactivity will be measured using VerifyNow (Accumetrics, San Diego, CA, USA) and vasodilator-stimulated phosphoprotein (VASP) phosphorylation. VASP/P2Y12 assay (BioCytex, Marseille, France) and FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) will be used. High on-Treatment Platelet Reactivity (HTPR) is defined as the result of platelet reaction unit (PRU) ≥242 and vasodilator-stimulated phosphoprotein (VASP) index ≥50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Platelet reactivity will be measured using VerifyNow (Accumetrics, San Diego, CA, USA) and vasodilator-stimulated phosphoprotein (VASP) phosphorylation. VASP/P2Y12 assay (BioCytex, Marseille, France) and FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) will be used. High on-Treatment Platelet Reactivity (HTPR) is defined as the result of platelet reaction unit (PRU) ≥242 and vasodilator-stimulated phosphoprotein (VASP) index ≥50%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>ST-Segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Prasugrel 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor 180 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel 60 mg</intervention_name>
    <description>Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.</description>
    <arm_group_label>Prasugrel 60 mg</arm_group_label>
    <other_name>Effient 60 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 180 mg</intervention_name>
    <description>Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.</description>
    <arm_group_label>Ticagrelor 180 mg</arm_group_label>
    <other_name>Brilinta 180 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ST-segment elevation myocardial infarction

          -  Undergoing primary PCI

          -  Aged between 20 and 80 years

        Exclusion Criteria

          -  History of stroke or transient ischemic attack

          -  Previous gastrointestinal bleeding within 6 months

          -  Bleeding diathesis

          -  Previous antiplatelet agent administrated

          -  Pre-procedural glycoprotein (Gp) IIb/IIIa inhibitors used (&lt;24 hours)

          -  Chronic oral anticoagulation treatment

          -  Contraindication to the antiplatelet treatment

          -  Hemoglobin &lt; 10 g/dl

          -  Platelet count &lt; 100,000/mm3

          -  Severe renal insufficiency (serum creatine&gt;2.5 mg/dl)

          -  Severe hepatic dysfunction (serum liver enzyme or bilirubin&gt;3 times normal limit)

          -  Sever chronic obstructive pulmonary disease (COPD) or bradycardia

          -  Body weight &lt; 50 kg
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moo Hyun Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University Hospital, Busan, Republic of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moo Hyun Kim, M.D.</last_name>
    <phone>+82-51-240-2976</phone>
    <email>kimmh@dau.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>DongA University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moo Hyun Kim, M.D.</last_name>
      <phone>+82-51-240-2976</phone>
      <email>kimmh@dau.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013 Apr 16;61(15):1601-6. doi: 10.1016/j.jacc.2013.01.024. Epub 2013 Mar 22.</citation>
    <PMID>23500251</PMID>
  </reference>
  <reference>
    <citation>Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20.</citation>
    <PMID>23169985</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 26, 2014</lastchanged_date>
  <firstreceived_date>February 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dong-A University</investigator_affiliation>
    <investigator_full_name>Moo Hyun Kim</investigator_full_name>
    <investigator_title>M.D. Director, Regional Clinical Trial Center. Professor, Dept. of Cardiology Dong-A Unicersity Hospital</investigator_title>
  </responsible_party>
  <keyword>ST-segment elevation myocardial infarction</keyword>
  <keyword>Prasugrel</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Platelet function test</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prasugrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
